Jaguar Health (JAGX) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Skye Bioscience is the larger company by market cap ($3.1 million vs $3.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAGX | SKYE |
|---|---|---|
| Share price | $0.227 | $0.70 |
| Market cap | $3.03M | $3.10M |
| 1-day change | -30.58% | -11.03% |
| EPS (TTM) | $-257.15 | $-7.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $11.51M | — |
| Revenue growth (YoY) | -1.52% | — |
| Net income (latest FY) | $-53.58M | $-55.92M |
| Gross margin | 67.21% | — |
| Operating margin | -398.82% | — |
| Net margin | -465.42% | — |
| 52-week high | $981.75 | $11.04 |
| 52-week low | $0.22 | $0.484 |
| Distance from 52-week high | -99.98% | -93.66% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +9614.29% |
| Average volume | 2.40M | 88.19K |
| Shares outstanding | 13.35M | 4.42M |
| Employees | 47 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jaguar Health
JAGX stock →Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
JAGX vs SKYE FAQ
Which is bigger, Jaguar Health or Skye Bioscience?
Skye Bioscience (SKYE) is larger, with a market capitalization of $3.10M compared with $3.03M for Jaguar Health (JAGX).
Are Jaguar Health and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.